EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vivos Therapeutics's Enterprise Value is $7.78 Mil.
Vivos Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.75 Mil. Therefore, Vivos Therapeutics's EV-to-FCF for today is -0.61.
The historical rank and industry rank for Vivos Therapeutics's EV-to-FCF or its related term are showing as below:
VVOS'
s EV-to-FCF Range Over the Past 10 Years
Min: -77.69 Med: -0.99 Max: -0.17
Current: -0.61
During the past 6 years, the highest EV-to-FCF of Vivos Therapeutics was -0.17. The lowest was -77.69. And the median was -0.99.
VVOS's EV-to-FCF is ranked worse than 100% of 365
companies
in the Medical Devices & Instruments industry
Industry Median: 27.93
vs VVOS: -0.61
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Vivos Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vivos Therapeutics's EV-to-FCF
For the Medical Devices subindustry, Vivos Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos Therapeutics's EV-to-FCF Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vivos Therapeutics's EV-to-FCF falls into.
Vivos Therapeutics's current Enterprise Value is $7.78 Mil.
Vivos Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Vivos Therapeutics's PE Ratio for today is calculated as:
Vivos Therapeutics's share price for today is $2.18.
Vivos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.050.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vivos Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Vivos Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Vivos Therapeutics (Vivos Therapeutics) Business Description
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VVOS has been successfully added to your 